September 08, 2020
1 min read

Reimbursement approved for Iluvien for noninfectious posterior uveitis in Scotland

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The Scottish Medicines Consortium has accepted Iluvien for prevention of relapse in recurrent noninfectious posterior segment uveitis, Alimera announced in a press release.

The decision was based on a cost-utility analysis of the PSV-FAI-001 clinical study, which compared Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) with standard treatment, including systemic corticosteroids or immunosuppressants, topical steroids, intraocular pressure reduction therapy, cataract removal and other elective ocular surgical procedures, according to the release.

“We continue to execute on our goal of expanding Iluvien’s availability and are pleased that physicians and patients of the National Health Service Scotland now have access to Iluvien for both our [noninfectious posterior uveitis] and diabetic macular edema indications throughout the United Kingdom,” Rick Eiswirth, Alimera president and CEO, said in the release.